Weilizhibo-B (09887) transferred a total market value of HK$364 million, accounting for 3.62%, transferred 4,0694 million shares from China Securities Registration and Settlement Hong Kong

The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, on July 31, Weilizhibo-B (09887) had a position change, with a total transfer market value of HK$364 million, accounting for 3.62%. The company's shareholders transferred 3.126,400 shares to Citibank and 4,0694 million shares were transferred from China Securities Registration and Settlement Hong Kong.

Verishibo-B announced that the China National Drug Administration (China Drug Administration) Drug Evaluation Center (CDE) has approved a new drug clinical trial application (IND) for its self-developed drug candidate Vilisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL-024) for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter phase IB/II study to evaluate the safety and efficacy of Virixine™ in combination therapy for mCRC. This milestone marks an important step in expanding the indications of Villisin™ in gastrointestinal tumors. The company's immunotherapy landscape further extends from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a type of cancer with highly unmet clinical needs.